Lilly 2Q Revenues: $5.8 billion (+8%) 2Q Earnings: $1.0 billion (+35%) YTD Revenues: $11.1 billion (+8%) YTD Earnings: $2.2 billion (-24%) Comments: The increase in worldwide volume was due to 8% pharmaceutical growth driven by Trulicity, with sales up 139% to $480.2 million and other new products, including Taltz ($139 million, +618%), Jardiance ($103.2 million, +157%), and Cyramza ($186.3 million, +27%). These increases were partially offset by decreased volumes for Cialis, flat at $627.3...